These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 17593575)

  • 1. The time is ripe.
    Mortimer M
    Nature; 2007 Jun; 447(7146):884. PubMed ID: 17593575
    [No Abstract]   [Full Text] [Related]  

  • 2. The quiet rise of the clinical contractor.
    Wadman M
    Nature; 2006 May; 441(7089):22-3. PubMed ID: 16672945
    [No Abstract]   [Full Text] [Related]  

  • 3. Commercializing clinical trials--risks and benefits of the CRO boom.
    Shuchman M
    N Engl J Med; 2007 Oct; 357(14):1365-8. PubMed ID: 17914036
    [No Abstract]   [Full Text] [Related]  

  • 4. India in demand.
    Marris E
    Nature; 2005 Feb; 433(7028):902-3. PubMed ID: 15729350
    [No Abstract]   [Full Text] [Related]  

  • 5. Consistent clinical research standards benefit patients around the world.
    Herring J
    Nat Med; 2011 Sep; 17(9):1036. PubMed ID: 21900910
    [No Abstract]   [Full Text] [Related]  

  • 6. Guinea-pigging: healthy human subjects for drug safety trials are in demand. But is it a living?
    Elliott C
    New Yorker; 2008 Jan; ():36-41. PubMed ID: 18265451
    [No Abstract]   [Full Text] [Related]  

  • 7. The special treatment.
    Osborne R
    Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770
    [No Abstract]   [Full Text] [Related]  

  • 8. A new niche for PPMs. Site management organizations expedite clinical trials.
    Jaklevic MC
    Mod Healthc; 1998 Mar; 28(11):82, 86. PubMed ID: 10178269
    [No Abstract]   [Full Text] [Related]  

  • 9. Stimulating pharmaceutical innovation in the EU.
    Annemans L; Cleemput I; Hulstaert F; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):235-9. PubMed ID: 21671690
    [No Abstract]   [Full Text] [Related]  

  • 10. Trial blazers.
    Hoag H
    Nature; 2006 Jul; 442(7101):480-1. PubMed ID: 16909504
    [No Abstract]   [Full Text] [Related]  

  • 11. An audience with... Jan M. Lundberg.
    Lundberg JM
    Nat Rev Drug Discov; 2005 Jun; 4(6):452. PubMed ID: 15959949
    [No Abstract]   [Full Text] [Related]  

  • 12. Reverse vaccinology on the cusp.
    Jones D
    Nat Rev Drug Discov; 2012 Feb; 11(3):175-6. PubMed ID: 22322255
    [No Abstract]   [Full Text] [Related]  

  • 13. Small study on industry trial sponsorship leads to big questions about quality and bias.
    Twombly R
    J Natl Cancer Inst; 2007 Jul; 99(13):988-90. PubMed ID: 17596566
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical setbacks for toll-like receptor 9 agonists in cancer.
    Schmidt C
    Nat Biotechnol; 2007 Aug; 25(8):825-6. PubMed ID: 17687345
    [No Abstract]   [Full Text] [Related]  

  • 15. John Dillinger and clinical trials.
    Casey R
    Can J Urol; 2007 Oct; 14(5):3715. PubMed ID: 17949530
    [No Abstract]   [Full Text] [Related]  

  • 16. Stroke treatment--light at the end of the tunnel?
    Garber K
    Nat Biotechnol; 2007 Aug; 25(8):838-40. PubMed ID: 17687351
    [No Abstract]   [Full Text] [Related]  

  • 17. Tysabri's troubles return.
    Hoag H
    Nat Biotechnol; 2008 Oct; 26(10):1061. PubMed ID: 18846062
    [No Abstract]   [Full Text] [Related]  

  • 18. Industry shifts focus to immunology and cancer.
    Ledford H
    Nature; 2008 Nov; 456(7218):6. PubMed ID: 19004069
    [No Abstract]   [Full Text] [Related]  

  • 19. Viewpoint: Sir Richard Sykes, DSc, FRS, FMedSci. Interview by Ingrid Torjesen, BSc.
    Sykes R
    Circulation; 2006 Jun; 113(22):f85-6. PubMed ID: 16754809
    [No Abstract]   [Full Text] [Related]  

  • 20. Charles Hugh-Jones. Interview by Asher Mullard.
    Hugh-Jones C
    Nat Rev Drug Discov; 2013 Dec; 12(12):900. PubMed ID: 24287774
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.